Opdivo plus Cabometyx approved in the EU for advanced renal cancer
Opdivo plus Cabometyx doubled progression-free survival compared to those receiving Pfizer’s Sutent in a Phase III trial
Read More
Tag: kidney cancer
NICE green light for immunotherapy Bavencio
Merck and Pfizer’s drug will now be available on the NHS in combination with axitinib as a first-line treatment for kidney cancer
Read More
NICE backs Bavencio combo for kidney cancer
The combination of an immunotherapy with a targeted antiangiogenic therapy offers patients a novel treatment option
Read More
Opdivo/Cabometyx combo hits targets in first-line kidney cancer
The combination significantly increased progression free survival when used as a first-line treatment
Read More
Keytruda combo wins FDA approval for RCC
The approval is based on results of the KEYNOTE-426 study, in which Keytruda in combination with Inlyta was found to reduce the risk of death by nearly half compared to Sutent.
Read More
NICE appraisal for BMS kidney cancer immunotherapy combination
The Institute gave a positive FAD to the Opdivo and Yervoy combination in renal cell carcinoma, approving funding via the Cancer Drugs Fund.
Read More
EMA validates Bavencio for review in advanced RCC
European regulators have validated Merck’s application Bavencio for review in kidney cancer.
Read More
Half of all kidney cancer patients initially misdiagnosed
Half of all patients with kidney cancer are initially misdiagnosed, data from Kidney Cancer UK’s patient survey has revealed.
Read More
Merck, Pfizer intend to file Bavencio, Inlyta combo
Merck KGaA and Pfizer say they intend to seek US approval of a combination of Bavencio and Inlyta for kidney cancer on the back of progression-free survival data from a late-stage trial.
Read More
Blood test could detect kidney cancer up to five years earlier
Scientists have discovered a marker in the blood that could predict the risk of developing kidney cancer.
Read More
Three cancer treatments approved for use on NHS Scotland
Three treatments have been approved for NHS funding in Scotland, bringing new options for gastroenteropancreatic tumours, lung and kidney cancers, but patients with multiple sclerosis will be unable to access Roche’s Ocrevus following a rejection by the SMC.
Read More
EU OKs first-line use of Ipsen’s Cabometyx
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
